Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 307

1.

Neuromyelitis optica spectrum disease characteristics in Isfahan, Iran: A cross-sectional study.

Ashtari F, Safaei A, Shaygannejad V, Najafi MA, Vesal S.

J Res Med Sci. 2017 Mar 15;22:41. doi: 10.4103/1735-1995.202142. eCollection 2017.

2.

Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence.

Etemadifar M, Salari M, Mirmosayyeb O, Serati M, Nikkhah R, Askari M, Fayyazi E.

J Res Med Sci. 2017 Feb 16;22:18. doi: 10.4103/1735-1995.200275. eCollection 2017. Review.

3.

Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remission.

Wang S, Yang T, Wan J, Zhang Y, Fan Y.

Brain Behav. 2017 Mar 10;7(4):e00648. doi: 10.1002/brb3.648. eCollection 2017 Apr.

4.

Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder.

Chen B, Wu Q, Ke G, Bu B.

Sci Rep. 2017 Apr 11;7(1):831. doi: 10.1038/s41598-017-00860-y.

5.

Adaptive Immunity Is the Key to the Understanding of Autoimmune and Paraneoplastic Inflammatory Central Nervous System Disorders.

Weissert R.

Front Immunol. 2017 Mar 23;8:336. doi: 10.3389/fimmu.2017.00336. eCollection 2017. Review.

6.

The Presence of Autoantibodies Against Vascular and Nervous Tissue in Sera From Patients with Neuro-Behçet's Disease.

Colpak Aİ, Kalyoncu U, Gürsoy Özdemir Y.

Noro Psikiyatr Ars. 2014 Jun;51(2):141-147. doi: 10.4274/npa.y6987. Epub 2014 Jun 1.

7.

Müller cells and retinal axons can be primary targets in experimental neuromyelitis optica spectrum disorder.

Zeka B, Lassmann H, Bradl M.

Clin Exp Neuroimmunol. 2017 Jan;8(Suppl Suppl 1):3-7. doi: 10.1111/cen3.12345. Epub 2017 Jan 11. Review.

8.

Large-Scale in-House Cell-Based Assay for Evaluating the Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder Based on New Diagnostic Criteria.

Kim Y, Kim G, Kong BS, Lee JE, Oh YM, Hyun JW, Kim SH, Joung A, Kim BJ, Choi K, Kim HJ.

J Clin Neurol. 2017 Apr;13(2):175-180. doi: 10.3988/jcn.2017.13.2.175. Epub 2017 Mar 6.

9.

Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G.

Yao X, Verkman AS.

Acta Neuropathol Commun. 2017 Feb 17;5(1):15. doi: 10.1186/s40478-017-0417-9.

10.
11.

Impact of the anti-aquaporin-4 autoantibody on inner retinal structure, function and structure-function associations in Japanese patients with optic neuritis.

Matsumoto Y, Mori S, Ueda K, Kurimoto T, Kanamori A, Yamada Y, Nakashima I, Nakamura M.

PLoS One. 2017 Feb 15;12(2):e0171880. doi: 10.1371/journal.pone.0171880. eCollection 2017.

12.

Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica.

Guo Y, Weigand SD, Popescu BF, Lennon VA, Parisi JE, Pittock SJ, Parks NE, Clardy SL, Howe CL, Lucchinetti CF.

Acta Neuropathol. 2017 Apr;133(4):597-612. doi: 10.1007/s00401-017-1682-1. Epub 2017 Feb 9.

13.

Rituximab therapy in pemphigus and other autoantibody-mediated diseases.

Ran NA, Payne AS.

F1000Res. 2017 Jan 27;6:83. doi: 10.12688/f1000research.9476.1. eCollection 2017. Review.

14.

Commentary.

Awada AA.

J Neurosci Rural Pract. 2017 Jan-Mar;8(1):138-139. doi: 10.4103/0976-3147.193554. No abstract available.

15.

Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study.

Valentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A.

Neurol Neuroimmunol Neuroinflamm. 2016 Dec 15;4(2):e317. doi: 10.1212/NXI.0000000000000317. eCollection 2017 Mar.

16.

Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro.

Takeshita Y, Obermeier B, Cotleur AC, Spampinato SF, Shimizu F, Yamamoto E, Sano Y, Kryzer TJ, Lennon VA, Kanda T, Ransohoff RM.

Neurol Neuroimmunol Neuroinflamm. 2016 Dec 19;4(1):e311. doi: 10.1212/NXI.0000000000000311. eCollection 2017 Jan.

17.

Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration.

Miske R, Gross CC, Scharf M, Golombeck KS, Hartwig M, Bhatia U, Schulte-Mecklenbeck A, Bönte K, Strippel C, Schöls L, Synofzik M, Lohmann H, Dettmann IM, Deppe M, Mindorf S, Warnecke T, Denno Y, Teegen B, Probst C, Brakopp S, Wandinger KP, Wiendl H, Stöcker W, Meuth SG, Komorowski L, Melzer N.

Neurol Neuroimmunol Neuroinflamm. 2016 Dec 5;4(1):e307. eCollection 2017 Jan.

18.

Aquaporins in the Spinal Cord.

Oklinski MK, Skowronski MT, Skowronska A, Rützler M, Nørgaard K, Nieland JD, Kwon TH, Nielsen S.

Int J Mol Sci. 2016 Dec 7;17(12). pii: E2050. Review.

19.

Retinal Morphology and Sensitivity Are Primarily Impaired in Eyes with Neuromyelitis Optica Spectrum Disorder (NMOSD).

Akiba R, Yokouchi H, Mori M, Oshitari T, Baba T, Sawai S, Kuwabara S, Yamamoto S.

PLoS One. 2016 Dec 9;11(12):e0167473. doi: 10.1371/journal.pone.0167473. eCollection 2016.

20.

Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis.

Matsuda R, Kezuka T, Umazume A, Okunuki Y, Goto H, Tanaka K.

Neuroophthalmology. 2015 Aug 25;39(5):213-219. eCollection 2015 Oct.

Supplemental Content

Support Center